Linezolid efficacy and safety

A retrospective Tokyo study

Mariko Ono, Takashi Ebihara, Satoshi Iwata, Junko Kizu

Research output: Contribution to journalArticle

Abstract

Linezolid(LZD), an anti-methicillin-resistant Staphylococcus aureus(MRSA) agent, exhibits potent clinical effects on MRSA infection, but reported by causes thrombocytopenia as a side effect. We retrospectively studied LZD efficacy and safety in 106 subjects (77 men and 29 women with a mean age of 65.0 years (18 to 91)) treated with LZD between 2006 and 2008. We studied their backgrounds, reasons for LZD administration, anti-MRSA agents administered prior to LZD therapy, and laboratory data based on medical records. Mean administration was 16.4 days (1 to 78). LZD was mostly administered for poor or no response to anti-MRSA therapy. Vancomycin and other anti-MRSA agents were administered to 60 of the 106 subjects. In 49, clinical efficacy was evaluated by infection control doctor, who found 61% efficacy. In 25 (37 episodes) of the 106, LZD side effects were seen within 14 days after administration start. During LZD therapy, platelet counts decreased to less than 100,000/μL in 10 of the 54, hemoglobin to less than 11 g/dL in 3 of the 6, and leukocytes to less than 4,000/μL in 12 of the 70. Among factors involved in thrombocytopenia in those whose platelet counts were within normal range (150,000 to 350,000/μL) before LZD therapy. In the thrombocytopenia group, administration was longer (p = 0.017), and subjects were older (p = 0.002). These results suggest that hematological examination is important for detecting thrombocytopenia early stage after LZD administration start. Adverse thrombocytopenic effects should be carefully observed, particularly in long-term LZD administration and in LZD administration for old subjects.

Original languageEnglish
Pages (from-to)163-171
Number of pages9
JournalJapanese Journal of Chemotherapy
Volume59
Issue number2
Publication statusPublished - 2011 Mar

Fingerprint

Linezolid
Tokyo
Retrospective Studies
Safety
Methicillin-Resistant Staphylococcus aureus
Thrombocytopenia
Platelet Count

Keywords

  • Linezolid
  • MRSA
  • Thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ono, M., Ebihara, T., Iwata, S., & Kizu, J. (2011). Linezolid efficacy and safety: A retrospective Tokyo study. Japanese Journal of Chemotherapy, 59(2), 163-171.

Linezolid efficacy and safety : A retrospective Tokyo study. / Ono, Mariko; Ebihara, Takashi; Iwata, Satoshi; Kizu, Junko.

In: Japanese Journal of Chemotherapy, Vol. 59, No. 2, 03.2011, p. 163-171.

Research output: Contribution to journalArticle

Ono, M, Ebihara, T, Iwata, S & Kizu, J 2011, 'Linezolid efficacy and safety: A retrospective Tokyo study', Japanese Journal of Chemotherapy, vol. 59, no. 2, pp. 163-171.
Ono M, Ebihara T, Iwata S, Kizu J. Linezolid efficacy and safety: A retrospective Tokyo study. Japanese Journal of Chemotherapy. 2011 Mar;59(2):163-171.
Ono, Mariko ; Ebihara, Takashi ; Iwata, Satoshi ; Kizu, Junko. / Linezolid efficacy and safety : A retrospective Tokyo study. In: Japanese Journal of Chemotherapy. 2011 ; Vol. 59, No. 2. pp. 163-171.
@article{233474cbf0c644138330c56f13fe0928,
title = "Linezolid efficacy and safety: A retrospective Tokyo study",
abstract = "Linezolid(LZD), an anti-methicillin-resistant Staphylococcus aureus(MRSA) agent, exhibits potent clinical effects on MRSA infection, but reported by causes thrombocytopenia as a side effect. We retrospectively studied LZD efficacy and safety in 106 subjects (77 men and 29 women with a mean age of 65.0 years (18 to 91)) treated with LZD between 2006 and 2008. We studied their backgrounds, reasons for LZD administration, anti-MRSA agents administered prior to LZD therapy, and laboratory data based on medical records. Mean administration was 16.4 days (1 to 78). LZD was mostly administered for poor or no response to anti-MRSA therapy. Vancomycin and other anti-MRSA agents were administered to 60 of the 106 subjects. In 49, clinical efficacy was evaluated by infection control doctor, who found 61{\%} efficacy. In 25 (37 episodes) of the 106, LZD side effects were seen within 14 days after administration start. During LZD therapy, platelet counts decreased to less than 100,000/μL in 10 of the 54, hemoglobin to less than 11 g/dL in 3 of the 6, and leukocytes to less than 4,000/μL in 12 of the 70. Among factors involved in thrombocytopenia in those whose platelet counts were within normal range (150,000 to 350,000/μL) before LZD therapy. In the thrombocytopenia group, administration was longer (p = 0.017), and subjects were older (p = 0.002). These results suggest that hematological examination is important for detecting thrombocytopenia early stage after LZD administration start. Adverse thrombocytopenic effects should be carefully observed, particularly in long-term LZD administration and in LZD administration for old subjects.",
keywords = "Linezolid, MRSA, Thrombocytopenia",
author = "Mariko Ono and Takashi Ebihara and Satoshi Iwata and Junko Kizu",
year = "2011",
month = "3",
language = "English",
volume = "59",
pages = "163--171",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Linezolid efficacy and safety

T2 - A retrospective Tokyo study

AU - Ono, Mariko

AU - Ebihara, Takashi

AU - Iwata, Satoshi

AU - Kizu, Junko

PY - 2011/3

Y1 - 2011/3

N2 - Linezolid(LZD), an anti-methicillin-resistant Staphylococcus aureus(MRSA) agent, exhibits potent clinical effects on MRSA infection, but reported by causes thrombocytopenia as a side effect. We retrospectively studied LZD efficacy and safety in 106 subjects (77 men and 29 women with a mean age of 65.0 years (18 to 91)) treated with LZD between 2006 and 2008. We studied their backgrounds, reasons for LZD administration, anti-MRSA agents administered prior to LZD therapy, and laboratory data based on medical records. Mean administration was 16.4 days (1 to 78). LZD was mostly administered for poor or no response to anti-MRSA therapy. Vancomycin and other anti-MRSA agents were administered to 60 of the 106 subjects. In 49, clinical efficacy was evaluated by infection control doctor, who found 61% efficacy. In 25 (37 episodes) of the 106, LZD side effects were seen within 14 days after administration start. During LZD therapy, platelet counts decreased to less than 100,000/μL in 10 of the 54, hemoglobin to less than 11 g/dL in 3 of the 6, and leukocytes to less than 4,000/μL in 12 of the 70. Among factors involved in thrombocytopenia in those whose platelet counts were within normal range (150,000 to 350,000/μL) before LZD therapy. In the thrombocytopenia group, administration was longer (p = 0.017), and subjects were older (p = 0.002). These results suggest that hematological examination is important for detecting thrombocytopenia early stage after LZD administration start. Adverse thrombocytopenic effects should be carefully observed, particularly in long-term LZD administration and in LZD administration for old subjects.

AB - Linezolid(LZD), an anti-methicillin-resistant Staphylococcus aureus(MRSA) agent, exhibits potent clinical effects on MRSA infection, but reported by causes thrombocytopenia as a side effect. We retrospectively studied LZD efficacy and safety in 106 subjects (77 men and 29 women with a mean age of 65.0 years (18 to 91)) treated with LZD between 2006 and 2008. We studied their backgrounds, reasons for LZD administration, anti-MRSA agents administered prior to LZD therapy, and laboratory data based on medical records. Mean administration was 16.4 days (1 to 78). LZD was mostly administered for poor or no response to anti-MRSA therapy. Vancomycin and other anti-MRSA agents were administered to 60 of the 106 subjects. In 49, clinical efficacy was evaluated by infection control doctor, who found 61% efficacy. In 25 (37 episodes) of the 106, LZD side effects were seen within 14 days after administration start. During LZD therapy, platelet counts decreased to less than 100,000/μL in 10 of the 54, hemoglobin to less than 11 g/dL in 3 of the 6, and leukocytes to less than 4,000/μL in 12 of the 70. Among factors involved in thrombocytopenia in those whose platelet counts were within normal range (150,000 to 350,000/μL) before LZD therapy. In the thrombocytopenia group, administration was longer (p = 0.017), and subjects were older (p = 0.002). These results suggest that hematological examination is important for detecting thrombocytopenia early stage after LZD administration start. Adverse thrombocytopenic effects should be carefully observed, particularly in long-term LZD administration and in LZD administration for old subjects.

KW - Linezolid

KW - MRSA

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=79953875457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953875457&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 163

EP - 171

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 2

ER -